Pulse corticosteroid therapy in interstitial lung disease-associated with anti-aminoacyl-tRNA synthetase antibodies: Comparable efficacy with potential for reduced adverse events - 24/04/25
, Toru Tanaka, Koichiro Kamio, Akihiko Miyanaga, Namiko Taniuchi, Yosuke Tanaka, Kazuo Kasahara, Masahiro SeikeAbstract |
Background and objective |
The optimal treatment modality for interstitial lung disease (ILD) associated with anti-aminoacyl-tRNA synthetase (ARS) antibodies remains controversial. This study aimed to compare the efficacy and safety of pulse corticosteroid therapy with that of conventional corticosteroid therapy in patients with anti-ARS ILD.
Methods |
This retrospective cohort study included 62 patients with anti-ARS ILD. Patients were divided into two groups: Those who received pulse corticosteroid therapy (500–1000 mg of methylprednisolone intravenously for three days) and those who received conventional corticosteroid therapy. Primary outcomes included initial treatment response at one year and disease recurrence. Secondary outcomes were alterations in pulmonary function tests, KL-6 levels, prednisolone dose, and adverse events.
Results |
Both the pulse corticosteroid therapy group and the conventional therapy group had similar rates of initial treatment improvement (90.3 % vs. 77.4 %, p = 0.301), with no significant differences in recurrence-free survival. Improvements in pulmonary function tests were comparable between the two groups. At 12 months, the mean daily prednisolone dose was 3.9 mg in the pulse therapy group compared with 6.0 mg in the conventional therapy group. The pulse corticosteroid therapy group also experienced fewer adverse events (25.8 % vs. 61.3 %, p = 0.010).
Conclusion |
Pulse corticosteroid therapy provides similar treatment efficacy, earlier reduction in corticosteroid dosage, and a lower incidence of adverse events compared to conventional therapy in patients with anti-ARS ILD. These findings highlight the potential benefit of a steroid-sparing strategy, suggesting that pulse corticosteroid therapy may be considered an effective and safer option in managing this condition.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Pulse corticosteroid therapy showed comparable efficacy to conventional therapy in anti-ARS ILD treatment. |
• | Earlier reduction in prednisolone dosage achieved with pulse therapy compared to conventional therapy. |
• | Pulse corticosteroid group had significantly fewer adverse events than conventional therapy group. |
• | KL-6 levels decreased more rapidly at 3 months in pulse therapy group, but equalized by 6 months. |
• | Pulse corticosteroid therapy may offer a favorable safety profile in managing anti-ARS ILD. |
Résumé |
This retrospective study compared pulse versus conventional corticosteroid therapy in anti-ARS antibody-associated interstitial lung disease. Pulse corticosteroid therapy showed comparable efficacy, earlier reduction in corticosteroid dosage, and fewer adverse events. These findings suggest pulse corticosteroid therapy as a viable treatment option, potentially offering a more favorable safety profile.
Le texte complet de cet article est disponible en PDF.Keywords : Anti-aminoacyl-tRNA synthetase antibodies, Interstitial lung disease, Polymyositis, Dermatomyositis, Pulse corticosteroid therapy, Adverse events
Plan
Vol 241
Article 108070- mai 2025 Retour au numéro
Article précédent
- Associations of comorbid heart disease and depression/anxiety with multidimensional breathlessness in COPD – A cross-sectional study
- Gabriella Eliason, Magnus Ekström, Scott Montgomery, Maaike Giezeman, Mikael Hasselgren, Christer Janson, Marta A. Kisiel, Karin Lisspers, Anna Nager, Hanna Sandelowsky, Björn Ställberg, Josefin Sundh
- Platelet activation and COPD-related clinical and imaging characteristics: The Multi-Ethnic Study of Atherosclerosis (MESA) COPD Study
- Carrie L. Pistenmaa, Eric A. Hoffman, Martin R. Prince, Emlyn Hughes, Stephen Dashnaw, Christian M. Lo Cascio, Elizabeth C. Oelsner, Wei Shen, Yanping Sun, Hinrich Winther, Jens Vogel-Claussen, Jim M. Wild, Russell P. Tracy, R. Graham Barr
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?